Clinical Trials
ABACUS-2
A phase II, randomised, controlled, double masked, multiple dose study of the safety, tolerability, and efficacy of intravitreal KIO-301 in participants with late-stage retinitis pigmentosa.
Overview
Kiora pharmaceuticals is conducting the Abacus-2 study – a Phase 2 randomised, controlled, double masked, multiple dose study of the safety, tolerability, and efficacy of intravitreal KIO-301 in participants with late-stage retinitis pigmentosa
Who may be eligible?
A patient may be able to participate in the clinical trial if they meet eligibility criteria including (but not limited to):
- Adults aged 18 years or older
- Diagnosis of non-syndromic RP, with the exception of Usher’s Syndrome Type II (USH2) which is allowed.
- Have a visual acuity as per the Berkeley Rudimentary Vision Test (BRVT) at Screening of:
- NLP OU confirmed by inability to see pen torch light at 25 cm OD, OS, and OU (assigned logMAR of 4.0), or
- LV OU limited to logMAR > 1.6 and < 4.0.
- Principal Investigator
Dr Doron Hickey
Kiora pharmaceuticals is conducting the Abacus-2 study – a Phase 2 randomised, controlled, double masked, multiple dose study of the safety, tolerability, and efficacy of intravitreal KIO-301 in participants with late-stage retinitis pigmentosa
Who may be eligible?
A patient may be able to participate in the clinical trial if they meet eligibility criteria including (but not limited to):
- Adults aged 18 years or older
- Diagnosis of non-syndromic RP, with the exception of Usher’s Syndrome Type II (USH2) which is allowed.
- Have a visual acuity as per the Berkeley Rudimentary Vision Test (BRVT) at Screening of:
- NLP OU confirmed by inability to see pen torch light at 25 cm OD, OS, and OU (assigned logMAR of 4.0), or
- LV OU limited to logMAR > 1.6 and < 4.0.
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.